« Return to News | Clinical Intelligence

Selexys Pharmaceuticals concludes phase I study in sickle cell disease

Thursday, June 14, 2012 11:54 AM

Selexys Pharmaceuticals, a privately held biopharmaceutical company based in Oklahoma City, Okla., has completed a phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

The placebo-controlled, double-blind, ascending single dose and multiple dose study of SelG1 enrolled 27 healthy subjects. The study evaluated the safety and pharmacology of SelG1 to support its advancement into a phase II clinical trial in patients with sickle cell disease.

SelG1 appeared to be safe and well tolerated, with no serious adverse events reported in any subjects. There was no observed immune response to SelG1 during the study. Analysis of SelG1 pharmacokinetic and pharmacodynamic data demonstrated a serum half-life of approximately two weeks and complete blockade of P-selectin activity in all patients for at least one month following a single intravenous dose.

"This phase I study represents a major step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and other indications," said Dr. Scott Rollins, president and CEO of Selexys.

In 2008, Selexys received orphan-drug designation for SelG1 from the FDAn Office of Orphan Products Development for the treatment of vasoocclusive crisis, a severe and painful complication of sickle cell disease.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.